This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2018
  • /
  • 12
  • /
  • European Commission approves Dengvaxia dengue vacc...
Drug news

European Commission approves Dengvaxia dengue vaccine.- Sanofi

Read time: 1 mins
Last updated:20th Dec 2018
Published:20th Dec 2018
Source: Pharmawand

The European Commission has granted marketing authorization for Dengvaxia, Sanofi's dengue vaccine. The marketing authorization follows the 18 October 2018, recommendation by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) to approve use of the dengue vaccine in European endemic areas.

Dengue fever is a mosquito-borne infection that people can get up to 4 times in a lifetime. Dengue is also known as 'break-bone fever' since it can cause debilitating disease marked by prolonged episodes of high fever and severe joint pain. An infection can progress unpredictably to a life-threatening form of the disease called dengue haemorrhagic fever that often requires hospitalized care. Today, there is no specific treatment available for dengue.

Dengvaxia will be available in Europe to prevent dengue disease in individuals 9-45 years of age with a documented prior dengue infection and who are living in endemic areas.

According to the WHO, the global incidence of dengue has grown rapidly in recent decades and it now threatens half of the world's population living in 128 countries. Dengue is endemic in several European territories located in tropical and sub-tropical climates prone to outbreaks of the disease particularly during the rainy season. Earlier this year, dengue outbreaks in La Reunion resulted in more than 6,000 people being made ill by the virus, which is spread by a day-biting mosquito that often lives in people's homes. During past outbreaks of dengue in Guadeloupe and Martinique, more than 40,000 people reportedly contracted the fever.

The dengue vaccine has been evaluated in studies involving more than 40,000 people from 15 countries with up to six years of follow-up from large-scale clinical safety and efficacy investigations.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.